Skip to content
10-Q

Quarterly Report

PARATEK PHARMACEUTICALS, INC.

0001564590-21-042629

← back to feed
Filed
Aug 9, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2021 · Jul 30, 2021 48.79M sh
Long Term Debt Q2 2021 · Jun 30, 2021 $252.76M
Long Term Debt Q2 2021 · Dec 31, 2020 $250.47M
Current Liabilities Q2 2021 · Jun 30, 2021 $20.98M
Current Liabilities Q2 2021 · Dec 31, 2020 $23.95M
Total Liabilities Q2 2021 · Jun 30, 2021 $278.88M
Total Liabilities Q2 2021 · Dec 31, 2020 $279.11M
Current Assets Q2 2021 · Jun 30, 2021 $153.5M
Current Assets Q2 2021 · Dec 31, 2020 $164.12M
Total Assets Q2 2021 · Jun 30, 2021 $179.59M
Total Assets Q2 2021 · Dec 31, 2020 $176.85M
Cash And Equivalents Q2 2021 · Dec 31, 2020 $105.16M
Cash And Equivalents Q2 2021 · Jun 30, 2020 $141.95M
Shares Diluted Q2 2021 · Jun 30, 2020 43.63M sh
Shares Diluted Q2 2021 · Jun 30, 2020 42.64M sh
Operating Cash Flow Q2 2021 · Jun 30, 2020 −$50.66M
Stockholders Equity Q2 2021 · Jun 30, 2020 −$63.46M
Stockholders Equity Q2 2021 · Mar 31, 2020 −$55.24M
Stockholders Equity Q2 2021 · Dec 31, 2019 −$39.65M
Eps Diluted Q2 2021 · Jun 30, 2020 −$0.53
Eps Diluted Q2 2021 · Jun 30, 2020 −$1.19
Eps Basic Q2 2021 · Jun 30, 2020 −$0.53
Eps Basic Q2 2021 · Jun 30, 2020 −$1.19
Sga Expense Q2 2021 · Jun 30, 2020 $20.98M
Sga Expense Q2 2021 · Jun 30, 2020 $44.61M
Net Income Q2 2021 · Jun 30, 2020 −$23.06M
Net Income Q2 2021 · Jun 30, 2020 −$50.68M
Net Income Q2 2021 · Mar 31, 2020 −$27.62M
Operating Income Q2 2021 · Jun 30, 2020 −$18.45M
Operating Income Q2 2021 · Jun 30, 2020 −$42.02M
Cost Of Revenue Q2 2021 · Jun 30, 2020 $2.24M
Cost Of Revenue Q2 2021 · Jun 30, 2020 $3.71M
Revenue Q2 2021 · Jun 30, 2020 $9.33M
Revenue Q2 2021 · Jun 30, 2020 $17.25M